Acute myeloid leukemia, version 3.2019

Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O'DonnellRebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, Lydia Hammond, Ndiya Ogba

Research output: Contribution to journalArticlepeer-review

132 Scopus citations

Abstract

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

Original languageEnglish (US)
Pages (from-to)721-749
Number of pages29
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number6
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Acute myeloid leukemia, version 3.2019'. Together they form a unique fingerprint.

Cite this